Newsroom

Sangart to Present at American Society of Hematology Annual Meeting

SAN DIEGO, CA (December 03, 2002) – Sangart, Inc., a biopharmaceutical company developing oxygen transport agents, announced today that its Chairman and CEO, Robert M. Winslow, M.D., will make a presentation titled: Autoregulation and Vasoconstriction: Foundation for a New Generation of Blood Substitutes, at the American Society of Hematology (ASH) 44th Annual Meeting on Monday, December 9, 2002 at 9:00 a.m. (ET). The meeting is being held at the Convention Center in Philadelphia, Pennsylvania, from December 6 - 10, 2002.

Dr. Winslow commented, "I look forward to discussing Sangart's innovative theory regarding autoregulatory mechanisms in arterioles at ASH this year. Through our research conducted in connection with the University of California, San Diego, we found that increased vascular resistance often leads to hypertension and clinical side effects. As a result, Sangart's oxygen transport agents are designed to work without triggering the oxygen-sensitive autoregulatory mechanisms in arterioles, thereby avoiding the harmful vasoconstriction caused by some earlier generation blood substitutes."

About Hemospan®

Hemospan® is a product that is designed to serve as an alternative for red blood cell transfusions. Hemospan® represents a revolutionary approach in oxygen transport technology and is distinct from blood substitute products that have languished in decades-old clinical research. Sangart's products are chemically modified hemoglobin solutions prepared from outdated human blood, designed specifically to maximize oxygen transport to tissues that need it most.

About Sangart

Sangart is a private biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as alternatives to blood transfusions. The products are chemically modified hemoglobin solutions prepared from outdated human blood, designed specifically to transport oxygen in a cell-free solution. Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow's group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. From this experience, Sangart designed its lead product, Hemospan®, using unique polyethylene glycol conjugation to create a hemoglobin-based product that is intended to serve as an alternative to donated blood.

The key breakthroughs in the development of Hemospan® were the understanding of the mechanisms of vasoconstriction and the development of simplified production methods that make the final product commercially viable. These breakthroughs laid the groundwork for Sangart's business concept of developing cost-effective oxygen carriers that can be used in lieu of transfused red blood cells during episodes of temporary blood loss, such as surgery or trauma.

To learn more about Sangart or Hemospan®, please visit www.sangart.com